Genetic polymorphisms associated with the development and clinical course of multiple sclerosis (review)

International Journal of Molecular Medicine

Volumn 28, Issue 4, 2011, Pages 467-479

  Kallaur, Ana Paula ^a   Kaimen Maciel, Damacio Ramoń ^a   Morimoto, Helena Kaminami ^a   Watanabe, Maria Angelica Ehara ^a   Georgeto, Seŕgio Murilo ^a   Reiche, Edna Maria Vissoci ^a  

^a STATE UNIVERSITY OF LONDRINA   (Brazil)

Author keywords

Genetic polymorphism; Major histocompatibility complex; Multiple sclerosis; Tumor necrosis factor ; Tumor necrosis factor

Indexed keywords

APOLIPOPROTEIN E; CHEMOKINE RECEPTOR CCR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FAS ANTIGEN; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; LYMPHOTOXIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PROTEOLIPID PROTEIN; RANTES; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

AMYOTROPHIC LATERAL SCLEROSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DEMYELINATION; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE RESISTANCE; GENE FREQUENCY; GENETIC POLYMORPHISM; HUMAN; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TH1 CELL;

HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MULTIPLE SCLEROSIS; POLYMORPHISM, GENETIC;

EID: 79960749012     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.731     Document Type: Review

References (126)

1. Miller JR: Esclerose múltipla. In: Tratado de Neurologia. 10th edition. Rowland LP and Merrit MD(eds). Guanabara Koogan, Rio de Janeiro, pp670-686, 2002.
2. Adams AD and Victor M: Neurologia. 6th edition. McGraw Hill, Rio de Janeiro, 1998.
3. Seboun E, Oksenberg JR and Hauser SL: Molecular and genetic aspects of multiple sclerosis. In: The Molecular and Genetic Basis of Neurological Disease. 2nd edition. Rosenberg RN, Prusiner SB, DiMauro S and Barchi RL(eds). Butterworth-Heinemann, Boston, pp631-660, 1997.
4. Poser CM: Multiple sclerosis, observations and reflections-a personal memoir. J Neurol Sci 107: 127-140, 1991.
5. Mcdonald WI, Compston A, Edan G, et al: Recommended diag-nostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50: 121-127, 2001.
6. Lublin FD and Reingold SC: Defining the clinical course of MS. Neurology 45: 907-911, 1996.
7. World Health Organization: Neurological Disorders: Public Health Challenges, WHO Press, Geneva, 2006.
8. Runmarker B and Andersen O: Prognostic factors in a multiple sclerosis incidence cohort with 25 years of follow-up. Brain 116: 117-134, 1993. (Pubitemid 23087038)
9. Mcfarland FH: Correlation between MR and clinical findings of disease activity in multiple sclerosis. AJNR Am J Neuroradiol 20: 1777-1778, 1999.
10. Raine CS and Scheinberg LC: On the immunopathology of plaque development and repair in multiple sclerosis. J Neuroimmunol 20: 189-201, 1988. (Pubitemid 19008415)
11. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M and Lassamann H: Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47: 707-717, 2000. (Pubitemid 30390191)
12. Polman CH, Reingold SC, Edan G, et al: Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann Neurol 58: 840-846, 2005. (Pubitemid 41746873)
13. Gonzalez-Scarano F, Grossman RI, Galetta S, Atlas SW and Silberberg DH: Multiple sclerosis disease activity correlates with gadolinium-enhanced magnetic resonance imaging. Ann Neurol 21: 300-306, 1987. (Pubitemid 17035287)
14. Sospedra M and Martin M: Immunology of multiple sclerosis. Ann Rev Immunol 23: 683-747, 2005. (Pubitemid 40563183)
15. Kaimen-Maciel DR, Reiche EM, Brum-Souza DG, et al: CCR5Ä32 genetic polymorphism associated with benign clinical course and magnetic resonance imaging findings in Brazilian patients with multiple sclerosis. Int J Mol Med 20: 337-344, 2007.
16. Girolami U, Anthony DC and Frosch MP: Osistema nervoso central. In: Robbins Patologia Estrutural e Funcional. 6th edition. Cotran RS, Kumar V and Collins T(eds). Guanabara Koogan, Rio de Janeiro, pp1198-1202, 2000.
17. Mcdonald WI and Ron MA: Multiple sclerosis: the disease and its manifestations. Philos Trans RSoc Lond B Biol Sci 354: 1615-1622, 1999.
18. Kantarci OH, Morales Y, Ziemer PA, et al: CCR5Ä32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis. J Neuroimmunol 169: 137-143, 2005. (Pubitemid 41527099)
19. Gold R, Hartung HP and Lassmann H: T-cell apoptosis in auto-immune diseases: termination of inflammation in the nervous system and other sites with specialized immune-defense mecha-nisms. Trends Neurosci 20: 399-404, 1997. (Pubitemid 27364510)
20. Wiley SR, Schooley K, Smolak PJ, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682, 1995. (Pubitemid 26091143)
21. Nitsch R, Bechmann I, Deisz RA, et al: Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet 356: 827-828, 2000.
22. Aktas O, Osmanova V, Beyer M, Brocke S and Zipp F: Therapeutic modulation of the TRAIL system in autoimmune CNS inflammation. J Neuroimmunol 118: 52, 2001.
23. Mycko M, Kowalski W, Kwinkovski M, et al: Multiple sclerosis: the frequency of allelic forms of tumor necrosis factor or lymphotoxin-alpha. J Neuroimmunol 84: 198-206, 1998. (Pubitemid 28248406)
24. Bugeja MJ, Booth D, Bennett B, Heard R, Rubio J and Stewart G: An investigation of polymorphisms in the 17q11.2-12 CCchemokine gene cluster for association with multiple sclerosis in Australians. BMC Med Genet 7: 64, 2006.
25. Simpson J, Rezaie P, Newcombe J, Cuzner ML, Male D and Woodroofe MN: Expression of the β-chemokine CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue. J Neuroimmunol 108: 192-200, 2000. (Pubitemid 30438767)
26. Szczucinski A and Losy J: Chemokines and chemokines recep-tors in multiple sclerosis. Potential targets for new therapies. Acta Neurol Scan 115: 137-146, 2007. (Pubitemid 46219205)
27. Kantarci OH, Andrade M and Weinshenker BG: Identifying disease modifying genes in multiple sclerosis. J Neuroimmunol 123: 144-159, 2002. (Pubitemid 34195616)
28. Martinez Doncel A, Rubio A, Arroyo R, et al: Interleukin-10 poly-morphisms in Spanish multiple sclerosis patients. J Neuroimmunol 131: 168-172, 2002.
29. Nakajima H, Fukuda K, Doi Y, et al: Expression of Th1/Th2-related chemokine receptors on peripheral Tcells and correlation with clinical disease activity in patients with multiple sclerosis. Eur J Neurol 52: 162-168, 2004. (Pubitemid 39551725)
30. Calderon TM, Eugenin EA, Lopez L, et al: Arole for CXCL12 (SDF-1alpha) in the pathogenesis of multiple sclerosis: regulation of CXCL12 expression in astrocytes by soluble myelin basic protein. J Neuroimmunol 111: 27-39, 2006. (Pubitemid 44108231)
31. Smith KJ and Mcdonald WI: The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease. Philos Trans RSoc Lond B Biol Sci 354: 1649-1673, 1999. (Pubitemid 29534432)
32. Achiron A: Chemokine polymorphisms: candidates for MS susceptibility and disease course. Int MS J11: 71-77, 2004.
33. Kantarci OH, Atkinson EJ, Hebrink DD, Mcmurray C and Weinshenker BG: Association of two variants in IL-1β and IL-1 receptor antagonist genes with multiple sclerosis. J Neuroimmunol 106: 220-227, 2000. (Pubitemid 30256096)
34. Schrijver HM, Crusius JB, Uitdehaag BM, et al: Association of interleukin 1 beta and inteleukin-1 receptor antagonist genes with disease severity in MS. Neurology 52: 595-599, 1999. (Pubitemid 29075610)
35. Mann CLA, Davies MB, Boggild M, et al: Polymorphisms at the IL-1RN and IL-1beta loci influence disability in multiple sclerosis. Mult Scler 4: 34, 1998.
36. Feakes R, Sawcer S, Broadley S, et al: Interleukin 1 receptor antagonist (IL-1ra) in multiple sclerosis. J Neuroimmunol 105: 96-101, 2000. (Pubitemid 30125434)
37. Pickard C, Mann C, Sinnott P, et al: Interleukin-10 (IL10) promoter polymorphisms and multiple sclerosis. J Neuroimmunol 101: 207-210, 1999. (Pubitemid 29516463)
38. Mäurer M, Kruse N, Giess R, Toyka KV and rieckmann P: Genetic variation at position -1082 of the interleukin 10 (IL10) promotor and the outcome of multiple sclerosis. J Neuroimmunol 104: 98-100, 2000. (Pubitemid 30100543)
39. Martinez-Caceres EM, Espejo C, Brieva L, et al: Expression of chemokine receptors in the different clinical forms of multiple sclerosis. Mult Scler 8: 390-395, 2002.
40. Luomala M, Lehtimaki T, Huhtala H, et al: Promoter polymor-phism of IL-10 and severity of multiple sclerosis. Acta Neurol Scand 108: 396-400, 2003. (Pubitemid 37464118)
41. Wergeland S, Beiske A, Nyland H, et al: IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis. Eur Neurol 2: 171-175, 2005. (Pubitemid 40278522)
42. Cavanillas ML, Alcina A, Núñez C, et al: Polymorphisms in the IL2, IL2RA and IL2RB genes in multiple sclerosis risk. Eur J Hum Genet 18: 794-799, 2010.
43. Kirk CW, Droogan AG, Hawkins SA, Mcmillan SA, Nevin NC, and Grahamn CA: Tumour necrosis factor microsatellites show association with multiple sclerosis. J Neurol Sci 147: 21-25, 1997. (Pubitemid 27117500)
44. McDonnell GV, Kirk CW, Middleton D, et al: Genetic association studies of tumor necrosis factor α and β and tumor necrosis factor receptor 1 and 2 polymorphisms across the clinical spectrum of multiple sclerosis. J Neurol 246: 1051-1058, 1999.
45. Bruce AJ, Boling W, Kindy MS, et al: Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat Med 2: 788-794, 1996. (Pubitemid 26225095)
46. Huizinga TW, Westendorp RG, Bollen EL, et al: TNF-α promoter polymorphisms, production and susceptibility to multiple sclerosis in different group of patients. J Neuroimmunol 72: 149-153, 1997. (Pubitemid 27062770)
47. Mäurer M, Kruse N, Giess R, Kyriallis K, Toyka KV and Rieckmann P: Gene polymorphism at position -308 of the tumor necrosis factor α promoter is not associated with disease progres-sion in multiple sclerosis patients. J Neurol 246: 949-954, 1999. (Pubitemid 29512168)
48. He B, Navikas V, Lundahl J, Söderström M and Hillert J: Tumor necrosis factor α-308 alleles in multiple sclerosis and optic neuritis. J Neuroimmunol 63: 143-147, 1995. (Pubitemid 26020718)
49. Lucotte G, Bathelier C and Mercier G: TNF-alpha polymorphisms in multiple sclerosis: no association with -238 and -308 promoter alleles, but the microsatellite allele a11 is associated with the disease in French patients. Mult Scler 6: 78-80, 2000. (Pubitemid 30218899)
50. Messer G, Spengler U, Jung MC, et al: Polymorphic structure of the tumor necrosis factor (TNF) locus: an Nco1 polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J Exp Med 173: 209-219, 1991.
51. Fernandez-Arquero M, Arroyo R, Rubio A, et al: Primary asso-ciation of a TNF gene polymorphism with susceptibility to multiple sclerosis. Neurology 53: 1361-1363, 1999. (Pubitemid 29480107)
52. Drulovic J, Popadic D, Mesaros S, et al: Decreased frequency of the tumor necrosis factor alpha -308 allele in Serbian patients with multiple sclerosis. Eur Neurol 50: 25-29, 2003. (Pubitemid 36736966)
53. Martinez A, Rubio A, Urcelay E, et al: TNF-376A marks suscep-tibility to MS in the Spanish population: a replication study. Neurology 62: 809-810, 2004. (Pubitemid 38298965)
54. Weinshenker BG, Hebrink D, Wingerchuck DM, et al: Genetic variants in the tumor necrosis factor receptor 1 gene in patients with MS. Neurology 52: 1500-1503, 1999. (Pubitemid 29190551)
55. Pras E, Aksentijevich I, Shinar Y, Kastner DL and Achiron A: Lack of evidence for an association between two genetic poly-morphisms in the tumor necrosis factor receptor 1 gene and multiple sclerosis in Ashkenazi Jews. Eur Neurol 46: 153-155, 2001. (Pubitemid 34701686)
56. Ehling R, Gassner C, Lutterotti A, et al: Genetics variants in the tumor necroses factor receptor IIgene in patients with multiple sclerosis. Tissue Antigens 63: 28-33, 2003.
57. Liu R, Paxton WA, Choe S, et al: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86: 367-377, 1996. (Pubitemid 26272077)
58. Simpson JE, Newcombe J, Cuzner ML and Woodroofe MN: Expression of monocyte chemoattractant protein-1 and other β-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J Neuroimmunol 84: 238-244, 1998.
59. Dean M, Carrington M, Winkler C, et al: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273: 1856-1862, 1996. (Pubitemid 26322495)
60. Samsom M, Libert F, Doranz BJ, et al: Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382: 722-724, 1996.
61. Martinson JJ, Chapman NH, Rees DC, Liu YT and Clegg JB: Global distribution of the CCR5 gene 32-basepair deletion. Nat Genet 16: 100-103, 1997. (Pubitemid 27198165)
62. Voevodin A, Samilchuk E and Dashti S: A survey for 32 nucle-otide deletion in the CCR-5 chemokine receptor gene (delta ccr-5) conferring resistance to human immunodeficiency virus type 1 in different ethnic groups and in chimpanzees. J Med Virol 55: 147-151, 1988.
63. Libert F, Cochaux P, Beckman G, et al: The deltaccr5 mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in Northeastern Europe. Hum Mol Genet 7: 399-406, 1998. (Pubitemid 28120628)
64. Sellebjerg F, Madsen HO, Jensen CV, Jenses J and Garred P: CCR5-Δ32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J Neuroimmunol 102: 98-106, 2000.
65. Barcellos LF, Schito AM and Rimmler JB: CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group. Immunogenetics 51: 281-288, 2000. (Pubitemid 30198882)
66. Schreiber K, Otura AB, Ryder LP, et al: Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRB1*1501, CCR5 deletion mutation, apolipoprotein E). Mult Scler 8: 295-298, 2002. (Pubitemid 34784756)
67. Kantor R, Bakhanashvili M and Achorin A: A mutated CCR5 gene may have favorable prognostic implications in MS. Neurology 61: 238-240, 2003. (Pubitemid 36875309)
68. Bennets BH, Teutsch SM, Buhler MM, Hjeard RN and Stewart GJ: The CCR5 deletion mutation fails to protect against multiple sclerosis. Hum Immunol 58: 52-59, 1997. (Pubitemid 28027413)
69. Gade-Andavolu R, Comings DE, Macmurray J, et al: Association of CCR5 delta 32 deletion with early death in multiple sclerosis. Genet Med 6: 126-131, 2004. (Pubitemid 38715503)
70. Silversides JA, Heggarty SV, Mcdonnell GV, Hawkins SA and Graham CA: Influence of CCR5 delta 32 polymorphism on multiple sclerosis susceptibility and disease course. Mult Scler 10: 149-152, 2004. (Pubitemid 38499906)
71. Ristic S, Lovrecic L, Starcevic-Cizmarevic A, et al: No association of CCR5-Δ32 gene mutation with multiple sclerosis in Croatian and Slovenian patients. Mult Scler 12: 360-362, 2006. (Pubitemid 43827194)
72. Waterhouse P, Penninger JM, Timms E, et al: Lympho-proliferative disorders with early lethality in mice deficient in Ctla-4. Science 270: 985-988, 1995.
73. Fukazawa T, Kikuchi S, Miyagishi R, et al: CTLA-4 gene poly-morphism is not associated with conventional multiple sclerosis in Japanese. J Neuroimmunol 159: 225-229, 2005. (Pubitemid 40126196)
74. Rasmussen HB, Kelly MA, Francis DA and Lausen J: CTLA-4 in multiple sclerosis. Lack of genetic association in a European population but evidence of interaction with HLA-DR2 among Shanghai Chinese. J Neuroimmunol 184: 143-147, 2001. (Pubitemid 32181364)
75. Alizadehet HM, Babron MC, Birebent B, et al: Genetic inter-action of CTLA-4 with HLA-DR15 in multiple sclerosis. Ann Neurol 54: 119-122, 2003. (Pubitemid 36764989)
76. Miyata M and Smith Jd: Apolipoprotein E allele-specific anti-oxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 14: 55-61, 1996.
77. Dousset V, Gayou A, Brochet B and Iron A: ApoE polymorphism in multiple sclerosis. Mult Scler 4: 357, 1998.
78. Evangelou N, Jackson M, Beeson D and Palace J: Association of the ApoE ε4 allele with disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 67: 203-205, 1999. (Pubitemid 29326953)
79. Hogh P, Oturai A, Screiber K and Blinkerberg M: Apolipo-protein E and multiple sclerosis: impact of the epsilon-4 allele on susceptibility, clinical and progression rate. Mult Scler 6: 226-230, 2000.
80. Masterman T, Hillert J, Lannfelt L and Corder EH: The ε4 allele for ApoE doubles the risk of long-term prognosis in multiple sclerosis. Am J Hum Genet 67: 1957, 2000.
81. Fazekas F, Strasser-Fuchs S, Schmidt H, et al: Apolipoprotein E genotype related differences in brain lesions of multiple sclerosis. J Neurol Neurosurg Pscychiatry 69: 25-28, 2000. (Pubitemid 30410410)
82. Chapman J, Vinokurov S, Achiron A, et al: ApoE genotype is a major predictor of long-term progression of disability in MS. Neurololy 56: 312-316, 2001. (Pubitemid 32144140)
83. Fazekas F, Strasser-Fuchs S, Kollegger H, et al: Apolipoprotein E epsilon4 is associated with rapid progression of multiple sclerosis. Neurology 57: 853-857, 2001. (Pubitemid 32845507)
84. Ferri C, Sciacca FL, Veglia F, et al: ApoE epsilon2-4 and -491 polymorphism are not associated with MS. Neurology 53: 888-889, 1999. (Pubitemid 29448324)
85. Weatherby SJ, Mann CL, Davies MB, et al: Polymorphisms of apolipoprotein E: outcome and susceptibility in multiple sclerosis. Mult Scler 6: 32-36, 2000. (Pubitemid 30175369)
86. Haines JL, Schmidt S, Boylston FR, et al: Follow-up analysis of the chromosome 19q13 region in multiple sclerosis with single-nucleotide polymorphisms. Neurology 56 (Suppl 3): A96, 2001.
87. Savettieri G, Andreoli V, Bonavita S, et al: Apolipoprotein E genotype does not influence the progression of multiple sclerosis. J Neurol 250: 1094-1098, 2003. (Pubitemid 37168017)
88. Niino M, Kikuchi S, Fukazawa T, Miyagishi R, Yabe I and Tashiro K: Na examination of the Apo-I/Fas Mva Ipolymorphism in Japanese patients with multiple sclerosis. BMC Neurol 2: 8, 2002.
89. Gong B and Almasan A: Genomic organization and transcrip-tional regulation of human Apo2/TRAIL gene. Biochem Biophys Res Commun 278: 747-752, 2000.
90. Weber A, Wandinger KP, Mueller W, et al: Identification and functional characterization of a highly polymorphic region in the TRAILpromoter in multiple sclerosis. J Neuroimmunol 149: 95-201, 2004.
91. Naito S, Namerow N, Mickey M and Terasaki PI: Multiple Sclerosis: association with HL-A3. Tissue Antigens 2: 1-4, 1972.
92. Jersild C, Svejgaard A and Fog T: HLA antigens and multiple sclerosis. Lancet 2: 240-241, 1972.
93. Winchester R, Ebers GC, Fu SM, Espinosa L, Zabriskie J and Kunkel HG: B-cell alloantigen Ag7a in multiple sclerosis. Lancet 2: 814, 1975.
94. Brautbar C, Amar A, Cohen I, et al: Histocompatibility (HLA) antigens and multiple sclerosis in Israelis. Isr J Med Sci 18: 631-634, 1982. (Pubitemid 12093752)
95. Compston DA: The genetic epidemiology of multiple sclerosis. Philos Trans R Soc B Biol Sci 354: 1623-1634, 1999.
96. Soderstrom M, Ya-Ping J, Hillert J and Link H: Optic neuritis prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology 50: 708-714, 1998.
97. Saruhan-Dirreskenel G, Esin S, Baykan-Kurt B, et al: HLA-DR and DQ associations with multiple sclerosis in Turkey. Hum Immunol 55: 59-65, 1997. (Pubitemid 27419323)
98. Coraddu F, Reyes-Yañes MP, Parra A, et al: HLA associations with multiple sclerosis in the Canary Islands. J Neuroimmunol 87: 130-135, 1998. (Pubitemid 28319853)
99. Marrosu MG, Murru MR, Costa G, Murru R, Muntoni F and Cucca F: DRB1-DQA1-DQB1 loci and multiple sclerosis predisposition in the Sardinian population. Hum Mol Genet 7: 1235-1237, 1998. (Pubitemid 28383055)
100. Compston DA, Batchelor JR and Mcdonald WI: B-lymphocyte alloantigens associated with multiple sclerosis. Lancet 2: 1261-1265, 1976.
101. Olerup O and Hillert J: HLA class II- associated genetic susceptibility in multiple sclerosis: a critical evaluation. Tissue Antigens 38: 1-15, 1991.
102. Fogdell A, Hillert J, Sachs C and Olerup O: The multiple sclerosis- and narcolepsy-associated HLA class IIhaplotype includes the DRB5*0101 allele. Tissue Antigens 4: 333-336, 1995.
103. Dyment DA, Stecklev JL, Morrison K, Willer CJ, Cader MZ, DeLuca GC, Sadovnick AD, Risch N, Ebers GC; Canadian Collaborative Study Group. TCRbeta polymorphisms and multiple sclerosis. Genes Immun 5: 337-342, 2004.
104. Zivadinov R, Uxa L, Zacchi T, et al: HLA genotypes and disease severity assessed by magnetic resonance imaging findings in patients with multiple sclerosis. J Neurol 250: 1099-1106, 2003. (Pubitemid 37152560)
105. Zivadinov R, Uxa L, Bratina A, et al: HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRIin patients with multiple sclerosis. Int Rev Neurobiol 79: 521-535, 2007.
106. Weinshenker BG, Santrach P, Bissonet AS, et al: Major histo-compatibility complex class alleles and the course and outcome of MS: a population-based study. Neurology 5: 742-747, 1998. (Pubitemid 28449253)
107. Silva A, Kesselring J and Thompson A: Frontiers in Multiple Sclerosis. Vol. 2. 1st edition. Martin Dunitz Ltd., London, pp51-61, 1999.
108. Hillert J: Human leukocyte antigen studies in multiple sclerosis. Ann Neurol 36: 15-17, 1994.
109. Marrosu MG, Murru MR, Costa G, et al: Multiple sclerosis in Sardinia is associated and in linkage disequilibrium with HLA-DR3 and -DR4 alleles. Am J Hum Genet 61: 454-457, 1997. (Pubitemid 27382324)
110. Gorodezky C, Najera R, Rangel BE, et al: Immunogenetic profile of multiple sclerosis in Mexicans. Hum Immunol 16: 364-374, 1986. (Pubitemid 16040254)
111. Ghabaee M, Bayati A, Amri Saroukolaei S, et al: Analysis of HLADR2&DQ6 (DRB1*1501, DQA1*0102, DQB1*0602) haplotypes in Iranian patients with multiple sclerosis. Cell Mol Neurobiol 20: 109-114, 2009.
112. Epplen C, Jackel S, Santos EJ, et al: Genetic predisposition to multiple sclerosis as revealed by immunoprinting. Ann Neurol 41: 341-352, 1997. (Pubitemid 27114045)
113. Vargas AE, Marrero AR, Salzano FM, Bortolini MC and Chies JA: Frequency of CCR5-Ä32 in Brazilian populations. Braz J Med Biol Res 39: 321-325, 2006.
114. Alves-Silva J, Da Silva Santos M, Guimara&tild;es PE, et al: The ancestry of Brazilian mtDNA lineages. Am J Hum Genet 67: 444-461, 2000. (Pubitemid 30616746)
115. Mikawa AY, Tagliavini SA and Costa PI: CCR5 genotype and plasma â-chemokine concentration of Brazilian HIV-infected individuals. Braz J Med Biol Res 35: 1333-1337, 2002. (Pubitemid 36013584)
116. Parra FC, Amado RC, Lambertucci JR, Rocha J, Antunes CM and Pena SD: Color and genomic ancestry in Brazilians. Proc Natl Acad Sci USA100: 177-182, 2003. (Pubitemid 36078048)
117. Pimenta JR, Zuccherato LW, Debes AA, et al: Color and genomic ancestry in Brazilians: a study with forensic micro-satellites. Hum Hered 62: 190-195, 2006. (Pubitemid 44971645)
118. Quirico-Santos T, Suppiah V, Heggarty S, Caetano R, Alves-Leon S and Vandenbroeck K: Study of polymorphisms in the interleukin-4 and IL-4 receptor genes in a population of Brazilian patients with multiple sclerosis. Arq Neuropsiquiatr 65: 15-19, 2007. (Pubitemid 46569525)
119. Passos GA Jr and Picanco V: Frequency of the delta CCR5 deletion in the urban Brazilian population. Immunol Lett 61: 205-207, 1998.
120. Caballero A, Alves-Leon S, Papais-Alvarenga R, Fernandez O, Navarro G and Alonso A: DQB1*0602 confers genetic suscep-tibility to multiple sclerosis in Afro-Brazilians. Tissue Antigens 54: 524-526, 1999.
121. Santos CC, Quirico-Santos T, Frugulhetti I and Alves-Leon SV: Analysis of HLA-DQ, DP, DR alleles associated with multiple sclerosis susceptibility in a population from Rio de Janeiro City. Arq Neuropsiquiatr 60: 1051, 2002.
122. Carvalho A, Sant'anna G, Santos CC, Frulhetti IP, Leon AS and Quírico-Santos T: Determination of autoantibody for myelin antigens in the serum of patients HLA-DQB1*0602 with multiple sclerosis. Arq Neuropsiquiatr 61: 968-973, 2003. (Pubitemid 38009305)
123. Alves-Leon SV, Papais-Alvarenga R, Magalha&tild;es M, Thuler LC, Fernandez Y and Fernandez O: Ethnicity-dependent association of HLADRB1-DQA1-DQB1 alleles in Brazilian multiple sclerosis patients. Acta Neurol Scand 115: 306-311, 2007. (Pubitemid 46705341)
124. Brum DG, Barreira AA, Louzada P Jr, Mendes CTJr and Donadi E: Association of the HLA-DRB1*15 allele group and DRB1*1501 and DRB1*1503 alleles with multiple sclerosis in White and Mulatto samples from Brazil. J Neuroimmunol 189: 118-124, 2007. (Pubitemid 47379422)
125. Kaimen-Maciel DR, Reiche EM, Borelli A, et al: HLA-DRB1* allele-associated genetic susceptibility and protection against multiple sclerosis in Brazilian patients. Mol Med Rep 2: 993-998, 2009.
126. Vasconcelos CC, Fernández O, Leyva L, Thuler LC and Alvarenga RM: Does the DRB1*1501 allele confer more severe and faster progression in primary progressive multiple sclerosis patients? HLA in primary progressive multiple sclerosis. J Neuroimmunol 214: 101-103, 2009.